AU2019317939A1 - Immunoreactant carrier - Google Patents

Immunoreactant carrier Download PDF

Info

Publication number
AU2019317939A1
AU2019317939A1 AU2019317939A AU2019317939A AU2019317939A1 AU 2019317939 A1 AU2019317939 A1 AU 2019317939A1 AU 2019317939 A AU2019317939 A AU 2019317939A AU 2019317939 A AU2019317939 A AU 2019317939A AU 2019317939 A1 AU2019317939 A1 AU 2019317939A1
Authority
AU
Australia
Prior art keywords
porous silica
silica particles
antibody
group
cytokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019317939A
Other languages
English (en)
Inventor
Cheol Hee Won
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lemonex Inc
Original Assignee
Lemonex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lemonex Inc filed Critical Lemonex Inc
Priority claimed from PCT/KR2019/006682 external-priority patent/WO2020032366A1/ko
Publication of AU2019317939A1 publication Critical patent/AU2019317939A1/en
Priority to AU2023208105A priority Critical patent/AU2023208105A1/en
Priority to AU2025226757A priority patent/AU2025226757A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Ceramic Engineering (AREA)
  • Microbiology (AREA)
  • Nanotechnology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2019317939A 2018-08-06 2019-06-03 Immunoreactant carrier Abandoned AU2019317939A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2023208105A AU2023208105A1 (en) 2018-08-06 2023-07-25 Immunoreactant carrier
AU2025226757A AU2025226757A1 (en) 2018-08-06 2025-09-04 Immunoreactant carrier

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862714874P 2018-08-06 2018-08-06
US62/714,874 2018-08-06
PCT/KR2019/006682 WO2020032366A1 (ko) 2018-08-06 2019-06-03 면역반응 물질 전달체
KR1020190065620A KR102316722B1 (ko) 2018-08-06 2019-06-03 면역반응 물질 전달체
KR10-2019-0065620 2019-06-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023208105A Division AU2023208105A1 (en) 2018-08-06 2023-07-25 Immunoreactant carrier

Publications (1)

Publication Number Publication Date
AU2019317939A1 true AU2019317939A1 (en) 2021-04-01

Family

ID=69670782

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2019317939A Abandoned AU2019317939A1 (en) 2018-08-06 2019-06-03 Immunoreactant carrier
AU2023208105A Abandoned AU2023208105A1 (en) 2018-08-06 2023-07-25 Immunoreactant carrier
AU2025226757A Pending AU2025226757A1 (en) 2018-08-06 2025-09-04 Immunoreactant carrier

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2023208105A Abandoned AU2023208105A1 (en) 2018-08-06 2023-07-25 Immunoreactant carrier
AU2025226757A Pending AU2025226757A1 (en) 2018-08-06 2025-09-04 Immunoreactant carrier

Country Status (8)

Country Link
US (1) US12343406B2 (cg-RX-API-DMAC7.html)
EP (1) EP3834820A4 (cg-RX-API-DMAC7.html)
JP (1) JP7688394B2 (cg-RX-API-DMAC7.html)
KR (1) KR102316722B1 (cg-RX-API-DMAC7.html)
CN (1) CN112543631B (cg-RX-API-DMAC7.html)
AU (3) AU2019317939A1 (cg-RX-API-DMAC7.html)
CA (1) CA3108251C (cg-RX-API-DMAC7.html)
SG (1) SG11202101258VA (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114113603B (zh) * 2021-06-30 2023-11-17 四川大学华西医院 Cytl1作为胃癌预后标志物的应用
CN113769099A (zh) * 2021-09-30 2021-12-10 佛山病原微生物研究院 一种asb17在制备traf6相关炎症性疾病药物中的用途
CN114558147A (zh) * 2022-03-14 2022-05-31 中国人民解放军空军军医大学 基于x射线激发的化疗-免疫疗法-光动力学三位一体联合治疗肿瘤的新型药物递送系统
CN117607461A (zh) * 2023-12-06 2024-02-27 陕西省动物研究所 一种s100a8蛋白的检测方法及其应用
CN120131968B (zh) * 2025-05-14 2025-07-29 广州医科大学附属第二医院 Trim3基因和/或其表达产物在制备治疗骨质疏松症的药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5202857B2 (ja) * 2007-03-13 2013-06-05 古河電気工業株式会社 分散性が高く、非特異的吸着を防止した複合粒子、複合粒子コロイド、それを用いた分析試薬、及び複合粒子の製造方法
US20110300186A1 (en) * 2010-04-14 2011-12-08 Battelle Memorial Institute Functionalized Nano- and Micro-materials for Medical Therapies
US20150272885A1 (en) * 2011-10-14 2015-10-01 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof
JP6004211B2 (ja) * 2012-02-29 2016-10-05 日産化学工業株式会社 有機溶媒分散シリカゾル及び有機溶媒分散シリカゾルの製造方法
US20150291764A1 (en) * 2012-10-10 2015-10-15 Dic Corporation Organic-inorganic hybrid silica nanoparticle and method for producing same
WO2016013751A1 (ko) * 2014-07-22 2016-01-28 주식회사 레모넥스 생리활성 물질 또는 단백질 전달용 조성물 및 이의 용도
JP5789335B1 (ja) * 2014-09-08 2015-10-07 明成化学工業株式会社 分散剤及び分散組成物
JP6868862B2 (ja) * 2015-08-31 2021-05-12 国立研究開発法人産業技術総合研究所 メソポーラスシリカ粒子
KR101924519B1 (ko) 2016-06-08 2018-12-04 광주과학기술원 펩타이드-키토산 개질 나노입자 및 이를 포함하는 약물 전달체
JP6883354B2 (ja) * 2017-02-06 2021-06-09 レモネックス インコーポレイテッドLemonex Inc. 生理活性物質送達体
WO2019022521A2 (ko) * 2017-07-25 2019-01-31 주식회사 레모넥스 혈관 내 생리활성물질 전달용 조성물
KR102152348B1 (ko) * 2017-09-05 2020-09-08 주식회사 레모넥스 세포 운명 조절용 조성물

Also Published As

Publication number Publication date
AU2023208105A1 (en) 2023-08-17
EP3834820A1 (en) 2021-06-16
KR102316722B1 (ko) 2021-10-26
JP7688394B2 (ja) 2025-06-04
SG11202101258VA (en) 2021-03-30
US20210177988A1 (en) 2021-06-17
JP2021532163A (ja) 2021-11-25
CN112543631A (zh) 2021-03-23
CA3108251A1 (en) 2020-02-13
KR102316722B9 (ko) 2022-12-08
CN112543631B (zh) 2022-12-06
KR20200016783A (ko) 2020-02-17
CA3108251C (en) 2024-04-23
AU2025226757A1 (en) 2025-09-25
US12343406B2 (en) 2025-07-01
EP3834820A4 (en) 2022-07-06

Similar Documents

Publication Publication Date Title
CA3108251C (en) Immunoreactant carrier
Shekhar et al. Interleukins profiling for biosensing applications: possibilities and the future of disease detection
KR102758037B1 (ko) Tg02의 다형성 형태
JP2023553010A5 (cg-RX-API-DMAC7.html)
Lin et al. Role of IFN-α in Rheumatoid Arthritis
AU2017238647A1 (en) Treatment of cancer with TG02
CN120712108A (zh) 具有可调整光学性质的大小可调整合成颗粒和用于使用其进行免疫细胞激活的方法
WO2026011826A1 (zh) 特异性识别cd276的核酸适体及其应用
CN1970789A (zh) 流式细胞仪-微载体基因芯片
US6677164B1 (en) Multivalent polymers, processes for their preparation, and their use for preparing biologically active compounds
CN102516339B (zh) 嘧啶并嘧啶化合物及其核苷类似衍生物和制备方法及用途
CN115282943B (zh) 一种可抑菌抗污的各向异性管状印迹吸附剂及其快速分离应用
WO2020032366A9 (ko) 면역반응 물질 전달체
Zakaria et al. Interleukin 28A. rs12980602 and interleukin 28B. rs8103142 genotypes could be protective against HCV infection among Egyptians
WO2001059096A9 (fr) Methode de detection d'un ligand ou d'un compose a faible poids moleculaire du type ligand
CN110183363B (zh) 一种甲基丙烯酸-3,4-二硫代羟己酯的衍生物及其制备方法与应用
CN111363822B (zh) 包含血液稳定性纳米颗粒的溶液、其制备方法及miRNA标志物的检测方法
CN115926787B (zh) 一种基于适配体修饰二氧化硅@石墨烯量子点的双光子信号放大探针的制备方法及应用
Ha et al. Gene expression profiling of human synovial sarcoma cell line (Hs701. T) in response to IL-1β stimulation
HK40106713A (en) Polymorphic form of tg02
CN115887695A (zh) 靶向dna高分子水凝胶材料的构建方法
Chen et al. CCL20 Signaling in the Tumor
Class et al. Patent application title: ENDOTOXIN NANOVESICLES: HYDROPHILIC GOLD NANODOTS CONTROL LIPOPOLYSACCHARIDE ASSEMBLY FOR MODULATING IMMUNOLOGICAL RESPONSES Inventors: Shu-Yi Lin (Miaoli County, TW) Yueh-Hsia Luo (Miaoli County, TW) Pinpin Lin (Miaoli County, TW)
CN119161545A (zh) 含氟聚合物、纳米粒子、纳米佐剂、纳米疫苗及其制备方法
CN119925638A (zh) 一种基于人乳头瘤病毒样颗粒的靶向递送载体及其在制备抗肿瘤药物中的应用

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted